Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

PRXV

Praxis Impact Large Cap Value ETF (PRXV)

Rating:72Outperform
Price Target:$40.00â–²(8.61% Upside)

PRXV, the Praxis Impact Large Cap Value ETF, earns a solid overall rating thanks to several high-quality blue-chip holdings like Micron, Merck, Johnson & Johnson, Walmart, and Cisco, which combine strong financial performance with growth drivers in areas such as AI, healthcare, and e-commerce. The fund is slightly held back by names like AbbVie and Procter & Gamble, where valuation and leverage concerns, along with some bearish technical signals, introduce more uncertainty. The main risk factor is that many core holdings face valuation and debt-related pressures, which could limit future upside if market conditions weaken.

Positive Factors
Strong Recent PerformanceThe ETF has shown strong gains so far this year, suggesting its strategy has been working well in the current market.
Solid Top HoldingsMany of the largest positions, including well-known financial, health care, consumer, and energy companies, have delivered strong year-to-date performance that supports the fund’s returns.
Broad Sector DiversificationThe fund spreads its investments across many sectors, which helps reduce the impact if any single industry faces a downturn.
Negative Factors
Single-Country FocusAlmost all of the ETF’s holdings are in U.S. companies, offering little protection if the U.S. market experiences a broad decline.
Moderate Expense RatioThe fund’s fees are not especially high but are also not among the lowest, which slightly reduces the net return investors receive.
Concentrated in Financials and Health CareA large portion of the portfolio is in financial and health care stocks, which could hurt performance if either of these sectors weakens.

PRXV vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%SPY+14.55%PRXV+27.49%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
97.40M
Region
North America
Expense Ratio
0.36%
Beta
0.53
Issuer
Praxis
Inception Date
Apr 07, 2025
Dividend Yield
1.46%
Asset Class
Equity
Index Tracked
No Underlying Index

PRXV Summary

Praxis Impact Large Cap Value ETF (PRXV) is a U.S. stock fund that focuses on large, established companies that appear undervalued and also meet strict environmental, social, and governance (ESG) standards. It doesn’t track a traditional index, but follows a value and impact theme, aiming to combine long-term growth with positive social outcomes. The fund holds well-known names like JPMorgan Chase, Johnson & Johnson, Walmart, and Coca-Cola, giving investors broad exposure to financials, health care, technology, and more. A key risk is that value stocks and the overall stock market can go up and down, so your investment may lose value.

How much will it cost me?

This ETF has an expense ratio of 0.36%, which means you’ll pay about $3.60 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because this fund is actively managed and also applies ESG screens, which generally cost more to run.

What would affect this ETF?

PRXV could benefit if the U.S. economy stays resilient, interest rates stabilize or fall (supporting its large financial holdings), and demand grows for healthcare, technology, and everyday consumer products, especially as more investors favor socially responsible companies. On the downside, higher interest rates, U.S.-focused economic slowdowns, pressure on banks or energy companies, or changes in ESG regulations and sentiment could weigh on the fund’s mainly U.S. large-cap value holdings.

PRXV Top 10 Holdings

PRXV leans heavily into U.S. financials and health care, with JPMorgan acting as a steady but not spectacular anchor while Micron’s recent pullback has slightly weighed on returns despite its strong year-to-date run. On the defensive side, Walmart, Coca-Cola, and Procter & Gamble are quietly doing the heavy lifting, with rising, resilient performance that smooths out volatility. AbbVie and Merck add more health care punch, mostly trending higher. Overall, the fund is a U.S.-centric, large-cap value play with a tilt toward banks, drugmakers, and a dash of tech cyclicality.

PRXV top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
JPMJPMJPMorgan Chase3.48%$3.41M$919.35B11.86%72Outperform
MUMUMicron3.43%$3.36M$880.60B228.47%79Outperform
JNJJNJJohnson & Johnson2.89%$2.83M$687.89B46.35%78Outperform
WMTWMTWalmart2.22%$2.18M$1.02T24.92%78Outperform
ABBVABBVAbbVie2.11%$2.07M$521.50B27.01%66Neutral
KOKOCoca-Cola1.84%$1.80M$426.96B39.65%75Outperform
PGPGProcter & Gamble1.82%$1.78M$393.56B14.76%69Neutral
CSCOCSCOCisco Systems1.43%$1.40M$376.53B23.60%77Outperform
MRKMRKMerck & Company1.41%$1.38M$364.26B59.00%80Outperform
HDHDHome Depot1.41%$1.38M$347.88B-5.27%66Neutral

PRXV Technical Analysis

Technical Analysis SentimentPositive
Last Price36.83

Price Trends

50DMA35.75Positive
100DMA35.64Positive
200DMA33.97Positive

Market Momentum

MACD0.29Negative
RSI59.11Neutral
STOCH79.46Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRXV, the sentiment is Positive. The current price of 36.83 is above the 20-day moving average (MA) of 36.37, above the 50-day MA of 35.75, and above the 200-day MA of 33.97, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 59.11 is Neutral, neither overbought nor oversold. The STOCH value of 79.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRXV.

PRXV Peer Comparison

Comparison Results

PRXV against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
PRXVPRXV$36.83$40.00(8.61% Upside)$97.40M0.36%72Outperform
MAVFMAVF$141.05$167.40(18.68% Upside)$93.69M0.75%74Outperform
NSIVNSIV$26.14$29.70(13.63% Upside)$74.39M0.38%72Outperform
PZLVPZLV$32.15$35.69(11.00% Upside)$73.18M0.60%68Neutral
DHLXDHLX$14.29$16.27(13.87% Upside)$69.44M0.55%73Outperform
MDLVMDLV$32.21$34.70(7.74% Upside)$48.85M0.58%68Neutral

Performance Comparison

0%10%20%PRXVMAVFNSIVPZLVDHLXMDLVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PRXV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PRXVPraxis Impact Large Cap Value ETF36.837.9627.58%
MAVFMatrix Advisors Value ETF141.0525.9522.55%
NSIVNorth Square Disciplined Value ETF26.141.054.20%
PZLVPzena U.S. Large Cap Value ETF32.157.0528.09%
DHLXDiamond Hill Large Cap Concentrated ETF14.291.7614.07%
MDLVMorgan Dempsey Large Cap Value ETF32.215.0418.53%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.